ABSTRACT Aim: To investigate the effect of COVID-19 on sexual dysfunction in women. Materials and Methods: The women diagnosed with COVID-19 and hospitalized at a tertiary hospital were included. They completed the Introductory Data Form, the Female Sexual Function Index-(FSFI), and the Short Form-36 Quality of Life Scale (SF-36). Results: 15 women between the ages of 19-49 who completed the treatment protocol, discharged at least 14 days before, and who had not been diagnosed as sexual dysfunction sexually active earlier were included to the study. It was detected that weekly sexual intercourse before and after COVID-19 significantly differed (p=0.047). The frequency of relationships decreased statistically after COVID-19. The mean value of the FSFI satisfaction score differs from COVID-19 before and after diagnosis (p=0.012). The mean satisfaction score before COVID-19 was 3.47, and after COVID-19 was 2.93. The score of the subgroups of FSFI did not differ from COVID-19 before and after diagnosis (p>0.050). The median value of SF-36 pain differs from COVID-19 before and after diagnosis (p=0.008). Conclusion: it was concluded that the frequency of sexual intercourse, sexual satisfaction in women decreased after COVID-19 disease, and the quality of life scores did not change in a statistically significant way.

Aim: To show if lower urinary tract symptoms (LUTS) could be symptoms of COVID-19 with validated questionnaires. Methods: The 96 COVID-19 patients who were hospitalized at a tertiary center were collected retrospectively. After the exclusion criteria, 46 patients were consisted as the study population. The male and female patients then fill formed the International Prostate Symptom Score and Urinary Symptom Profile respectively. All patients responded to these questions for the three period. Results: 27 female (58.6 %) and 19 male (41.4 %) COVID-19 patients answered the questions In the male patients, while there were no statistically significant differences in the total IPSS, the voiding IPSS score, and quality of life between the three periods (p=0.148; p=0.933, p=0.079, respectively), the storage IPSS scores had a significant difference between the three periods (p=0.05). In the female patients, low stream scores, were similar between the three periods (p=0.368). The scores of stress incontinence and an overactive bladder had a significant difference between the three periods (p=0.05 and p=0.05). Conclusion: LUTS, especially storage symptoms, might be one of the initial symptoms of COVID-19 and the clinicians should evaluate LUTS with other known symptoms of the virus when a patient is suspected of having COVID-19.

Backgrounds: To investigate the association between assisted reproductive technology (ART) treatments and the Coronavirus Disease 2019 (COVID-19). Methods: The data of the 17 infertility patients who were treated with ART between 01 and 11 March 2020 at a Reproductive Endocrinology and Infertility Unit of a tertiary center were collected retrospectively. The patients were then asked if they were positive for the COVID-19 or had symptoms of the illness. Results: Ovarian stimulation, oocyte pick-up, and intracytoplasmic sperm injection were used for all of the patients. Nine (52.9%) patients’ embryos were transferred and pregnancy was detected in 4 of the 9 patients after the assisted reproductive treatments. At the time of the interview, none of the infertile women had any symptoms of the COVID-19 or a confirmed diagnosis from a positive test result for the COVID-19 nucleic acids by real-time fluorescence reverse transcription-polymerase chain reaction. Conclusion: When turning to normal practice life, all patients should be evaluated for COVID-19 during pre, per and post-treatment time in order to stop the ART and protect against the cases from the possible side effects of assisted reproductive treatments, especially the possible, but undefined, predisposition factor to COVID-19.